Is InMed Pharmaceuticals going out of business?

InMed Pharmaceuticals Inc. (INM) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

InMed Pharmaceuticals Inc. (INM) scores 22 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 395.74% (YoY)

Five questions, kept separate

Survival - Critical

4-6 mo of estimated runway from 2026-03-31, based on $5.2M of cash and short-term investments against $13.0M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

204.1% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 395.74% (YoY)
• Debt / Equity: -0.69x (Net Cash)
• Filing event risk: Going-Concern Warning (-8 pts)
• Revenue CAGR (3Y): 65.55%
• R&D intensity: 45.22%
• Return on Assets: -89.36%
• Price / Sales: 0.9x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-07-22.

Price as of 2026-09-07.